Leerink Partnrs Has Pessimistic Outlook of MLTX Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share (EPS) estimate for MoonLake Immunotherapeutics to ($0.96), down from a previous estimate of ($0.80).
• The consensus estimate for the company's full-year earnings in 2025 stands at ($1.79) EPS, with projections predicting further losses through 2027 before potentially returning to profit in 2028.
• Despite the negative earnings outlook, MoonLake Immunotherapeutics has an average rating of "Moderate Buy" from analysts and an average price target of $74.43.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for MoonLake Immunotherapeutics in a research note issued on Tuesday, August 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($0.96) for the quarter, down from their prior estimate of ($0.80). The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($5.29) EPS, FY2028 earnings at $1.45 EPS and FY2029 earnings at $7.85 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter last year, the business posted ($0.39) EPS.

A number of other equities analysts have also issued reports on MLTX. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target on the stock in a research report on Monday, May 19th. The Goldman Sachs Group boosted their price objective on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Redburn Atlantic raised MoonLake Immunotherapeutics to a "hold" rating in a research note on Monday, July 28th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $80.00 price target (up from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, MoonLake Immunotherapeutics has a consensus rating of "Moderate Buy" and an average price target of $74.43.

MoonLake Immunotherapeutics Price Performance

Shares of MoonLake Immunotherapeutics stock traded up $0.92 on Friday, hitting $54.30. The company had a trading volume of 151,143 shares, compared to its average volume of 479,986. The business has a 50-day simple moving average of $49.11 and a 200-day simple moving average of $43.16. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. The company has a market cap of $3.48 billion, a PE ratio of -19.59 and a beta of 1.27. MoonLake Immunotherapeutics has a 52 week low of $31.42 and a 52 week high of $58.26.

Institutional Trading of MoonLake Immunotherapeutics

Several large investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its stake in shares of MoonLake Immunotherapeutics by 7.3% during the second quarter. Legal & General Group Plc now owns 20,905 shares of the company's stock valued at $987,000 after purchasing an additional 1,425 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of MoonLake Immunotherapeutics by 4,584.5% during the second quarter. JPMorgan Chase & Co. now owns 39,397 shares of the company's stock valued at $1,860,000 after purchasing an additional 38,556 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of MoonLake Immunotherapeutics by 0.9% during the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company's stock valued at $2,809,000 after purchasing an additional 559 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the second quarter valued at about $2,941,000. Finally, Woodline Partners LP boosted its stake in shares of MoonLake Immunotherapeutics by 0.9% during the first quarter. Woodline Partners LP now owns 296,148 shares of the company's stock valued at $11,571,000 after purchasing an additional 2,613 shares in the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.